Item 7.01 Regulation FD Disclosure.

On November 28, 2022, CinCor Pharma, Inc. (the "Company") issued a press release announcing the topline results and completion of its Phase 2 HALO trial evaluating the efficacy and safety of its lead clinical candidate, baxdrostat, in patients with uncontrolled hypertension taking up to two blood pressure medications at the maximally tolerated doses. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

The Company will host a conference call and webcast in connection with the above-referenced announcement at 8:00 a.m., Eastern Time, on November 28, 2022. A live audio webcast of the presentation will be available under "Events and Presentations" in the "Investors" section of the Company's website at www.cincor.com. The webcast will be archived on the Company's website for at least 30 days following the call. Details regarding the conference call and webcast can be found in the press release. The corporate presentation regarding the Phase 2 HALO trial results that the Company will be presenting on the conference call and webcast will be made available under "Events and Presentations" in the "Investors" section of the Company's website at www.cincor.com.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. The Company's website and the information contained on, or that can be accessed through, the Company's website will not be deemed to be incorporated by reference in, and are not considered part of, this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.
Exhibit No.   Description
99.1            Press Release issued by CinCor Pharma, Inc., dated November 28, 2022
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses